Troxerutin prices in the Asian market witnessed a sharp decline in the first half of July 2025, following a significant drop in June. The decrease was driven by oversupplied conditions, falling input costs, and weak demand from pharmaceutical and healthcare sectors in China and India. With high inventories and cautious procurement, market experts expect further price declines in the second half of July due to subdued buying momentum and soft downstream demand.
The prices of Troxerutin recorded a strong downward trend in the first half of July 2025 in the Asian market, thus continuing the sharp decline in the month of June. This continued price adjustment has largely been blamed on the oversupplied situation, fall in input costs, and decline in the downstream demand in the major consuming sectors, especially in China and India.
In China, Troxerutin prices declined steeply in June due to significant build up at supplier level. Excessive inventory pressure forced manufacturers to embark on vigorous price reduction to liquidate inventories. This was in addition to the ongoing reduction in the input costs that recorded the fourth straight month of easing in raw materials prices that have significantly reduced the costs of production. The decline in the output prices was the deepest in five months and the seventh consecutive fall in output prices noting that the market was structurally oversupplied.
Export demand for Troxerutin was also subdued as new overseas orders slowed with a reduced rate compared to that of May. To further compound the problems of exports, further depreciation of the U.S. Dollar against the Chinese Yuan raised the relative price of Chinese products, further compromising PRC export competitiveness, and enhancing further the decline of international demand. A combination of macroeconomic and supply-side factors led to the sustained downward influence on Troxerutin prices in China.
The same trend was also reflected in the Indian market. Troxerutin prices in India declined significantly in June, with significant reduction in import costs as a result of lower prices being offered aggressively by Chinese exporters due to accumulation of large inventory. Arrival of cheap imports enabled the Indian importers to purchase the material at lesser prices whereas the high business inventories impaired the emphasis on new acquisitions. The advent of a monsoon season discouraged bulk purchases further, and the local distributors gave discounts in order to sell, as well as to maintain its cash flow.
The slight appreciation of the USD against the Indian Rupee over the period did not manage to counteract the bigger downward force of stagnating global prices and oversupply at the domestic level. In addition, the increase in freight charges disincentivized importers to make bulk orders thereby further constricting trade volumes on Troxerutin. The combination of these factors put a long-term pressure on the Indian prices of Troxerutin.
ChemAnalyst reported that on the demand side, the pharmaceutical and healthcare industries in both China and India displayed poor Troxerutin offtake in June 2025. Procurement by end-users in China was cautious as they resorted to existing stocks because of poor market signals and decline in demand. The recovery in domestic demand was marginal; inadequate to offset the decreasing exports. The seasonal demand for Troxerutin was not observed in India, and importers adopted a restrained purchasing style, thereby causing the minimum purchasing activity in India. As it had sufficient quantities and low consumption patterns, purchasers decided just to meet short-term production demands, postponing bulk orders.
Market analysts have forecast that Troxerutin prices in Asia will continue to plunge downwards during the second half of July 2025. The Troxerutin market is in oversupply, and the buying pace is expected to drop further as customers stick to existing stocks. Also, the decrease in downstream industries demand of Troxerutin is expected to decrease market tightness further, supporting the bearish and prolonging its recent price downturn.
